Online citations, reference lists, and bibliographies.
← Back to Search

[Pyr1]-Apelin-13 Delivery Via Nano-liposomal Encapsulation Attenuates Pressure Overload-induced Cardiac Dysfunction.

Vahid Serpooshan, Senthilkumar Sivanesan, Xiaoran Huang, M. Mahmoudi, A. Malkovskiy, M. Zhao, M. Inayathullah, D. Wagh, Xuexiang J Zhang, Scott Metzler, D. Bernstein, J. Wu, P. Ruiz-Lozano, J. Rajadas
Published 2015 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Nanoparticle-mediated sustained delivery of therapeutics is one of the highly effective and increasingly utilized applications of nanomedicine. Here, we report the development and application of a drug delivery system consisting of polyethylene glycol (PEG)-conjugated liposomal nanoparticles as an efficient in vivo delivery approach for [Pyr1]-apelin-13 polypeptide. Apelin is an adipokine that regulates a variety of biological functions including cardiac hypertrophy and hypertrophy-induced heart failure. The clinical use of apelin has been greatly impaired by its remarkably short half-life in circulation. Here, we investigate whether [Pyr1]-apelin-13 encapsulation in liposome nanocarriers, conjugated with PEG polymer on their surface, can prolong apelin stability in the blood stream and potentiate apelin beneficial effects in cardiac function. Atomic force microscopy and dynamic light scattering were used to assess the structure and size distribution of drug-laden nanoparticles. [Pyr1]-apelin-13 encapsulation in PEGylated liposomal nanocarriers resulted in sustained and extended drug release both in vitro and in vivo. Moreover, intraperitoneal injection of [Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrated a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction. We concluded that this engineered nanocarrier system can serve as a delivery platform for treating heart injuries through sustained bioavailability of cardioprotective therapeutics.
This paper references
10.4103/0976-500X.72350
Blood sample collection in small laboratory animals
S. Parasuraman (2010)
10.1007/s00380-013-0425-z
Cardioprotective effects of adipokine apelin on myocardial infarction
Bao-hai Zhang (2013)
Erratum: Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy (Proc. Natl. Acad. Sci. USA (September 1991) 88 (8277-8281))
H. Rockman (1991)
10.1161/HYPERTENSIONAHA.109.134619
[Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease
J. Maguire (2009)
10.1111/j.1476-5381.2010.00821.x
Modulation of the apelin/APJ system in heart failure and atherosclerosis in man
Sarah L. Pitkin (2010)
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
D. Drummond (1999)
10.1021/ja107583h
Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles.
M. Monopoli (2011)
10.1016/S0378-5173(98)00408-6
Pharmacodynamics of insulin in polyethylene glycol-coated liposomes.
A. Kim (1999)
10.1038/nm0504-467
A decade of discoveries in cardiac biology
E. Olson (2004)
10.1016/S0076-6879(05)91002-1
Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
D. Waterhouse (2005)
Sustained release of growth factors. Vivo Athens Greece 2002;16:535e40
SN Robinson (2002)
10.1152/AJPREGU.2001.281.6.R2029
Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat.
M. Iemitsu (2001)
10.1016/J.JCONREL.2005.03.005
Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies.
Y. Xie (2005)
10.1021/JA066929M
Targeted drug delivery utilizing protein-like molecular architecture.
E. Rezler (2007)
10.1016/j.addr.2010.05.006
Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy.
M. Mahmoudi (2011)
10.1002/bip.22498
Stability and degradation patterns of chemically modified analogs of apelin‐13 in plasma and cerebrospinal fluid
A. Murza (2014)
10.1111/j.1471-4159.2004.02591.x
Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure
S. E. Messari (2004)
10.3791/1729
Transverse aortic constriction in mice.
A. deAlmeida (2010)
Acute phase response in animals: a review.
C. Cray (2009)
10.1161/JAHA.113.000249
Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia‐reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues
Wang Wang (2013)
Acute Phase Proteins Molecular Biology, Biochemistry, and Clinical Applications
A. Mackiewicz (1993)
10.2217/nnm.13.16
Nanoparticles and the cardiovascular system: a critical review.
K. Donaldson (2013)
10.1152/AJPHEART.2001.281.3.H1104
LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice.
A. Nakamura (2001)
10.4103/2045-8932.87299
Apelin and pulmonary hypertension
C. Andersen (2011)
10.1038/sj.bjp.0703939
[125I]‐(Pyr1)Apelin‐13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
S. D. Katugampola (2001)
10.1253/CIRCJ.CJ-11-0689
Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure.
Wataru Koguchi (2012)
10.1161/CIRCRESAHA.107.158659
Impaired Heart Contractility in Apelin Gene–Deficient Mice Associated With Aging and Pressure Overload
Keiji Kuba (2007)
Acute phase reaction and acute phase proteins
J. KOOPMANSS. (2005)
10.1016/0005-2736(92)90194-Q
Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes.
M. Woodle (1992)
10.1016/j.peptides.2013.05.006
Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction
Y. Azizi (2013)
10.1016/J.IJPHARM.2004.11.037
Drug interaction and location in liposomes: correlation with polar surface areas.
G. E. El Maghraby (2005)
10.1056/NEJM199005313222203
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.
D. Lévy (1990)
10.1007/978-1-59745-430-8_10
Peptide-mediated targeting of liposomes to tumor cells.
E. Rezler (2007)
Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility
IstvánSzokodi (2002)
10.1016/J.EJPS.2005.03.008
Targeting liposomes with protein drugs to the blood-brain barrier in vitro.
C. Visser (2005)
10.1016/S0169-409X(02)00022-4
Chemistry for peptide and protein PEGylation.
M. Roberts (2002)
10.2217/17435889.2.2.143
Nanoparticulate carriers for the treatment of coronary restenosis
L. Brito (2007)
10.1055/S-2007-971067
Plasma apelin is lower in patients with elevated LDL-cholesterol.
I. Tasci (2007)
10.1016/0735-1097(93)90213-K
Myocardial injury: the acute phase response and lipoprotein metabolism.
R. Rosenson (1993)
10.1371/journal.pone.0055424
Phenotyping of Left and Right Ventricular Function in Mouse Models of Compensated Hypertrophy and Heart Failure with Cardiac MRI
Bastiaan J. van Nierop (2013)
10.1038/nature11263
APJ ACTS AS A DUAL RECEPTOR IN CARDIAC HYPERTROPHY
M. C. Scimia (2012)
10.1016/S0005-2736(01)00327-3
Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells.
D. Fenske (2001)
10.2174/1381612043383467
Targeted liposomal drug delivery in cancer.
O. Medina (2004)
10.7326/0003-4819-114-5-345
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.
M. Koren (1991)
10.1152/ajpheart.01341.2008
Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation.
N. Leeper (2009)
10.1016/j.regpep.2007.10.002
Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase
M. J. Kleinz (2008)
10.1006/BBRC.1998.9489
Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.
K. Tatemoto (1998)
10.1038/nrd1033
Effect of pegylation on pharmaceuticals
J. Harris (2003)
10.1016/j.biotechadv.2012.10.002
Gold nanoparticles: emerging paradigm for targeted drug delivery system.
Anilesh Kumar (2013)
10.1379/1466-1268(2002)007<0036:ASITII>2.0.CO;2
Acute stress-induced tissue injury in mice: differences between emotional and social stress
O. Sánchez (2002)
10.1016/j.jconrel.2011.03.012
Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
Golam Kibria (2011)
10.1016/0024-3205(95)02086-X
Topical delivery of growth hormone releasing peptide using liposomal systems: an in vitro study using hairless mouse skin.
D. Fleisher (1995)
10.1039/C4BM00131A
Personalized protein coronas: a "key" factor at the nanobiointerface.
M. Hajipour (2014)
New therapeutic targets for the development of positive inotropic agents.
J. Tamargo (2011)
10.2147/IJN.S33541
Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats
Zhongya Chen (2012)
10.1016/S0168-3659(01)00505-3
Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery.
B. J. Lestini (2002)
10.1016/J.CARDIORES.2004.08.018
The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.
E. Ashley (2005)
10.1038/nnano.2012.207
Biomolecular coronas provide the biological identity of nanosized materials.
M. Monopoli (2012)
10.2147/IJN.S596
Drug delivery and nanoparticles: Applications and hazards
W. D. de Jong (2008)
10.1023/A:1023402123119
N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor
H. Lee (2004)
10.1161/CIRCULATIONAHA.109.911339
Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure
A. Japp (2010)
Stability and degradation patterns of chemically modi fi ed analogs of apelin - 13 in plasma and cerebrospinal fl uid
A Murza (2014)
10.1016/j.addr.2012.09.037
Liposomal drug delivery systems: from concept to clinical applications.
T. Allen (2013)
10.4155/bio.12.259
MS-based approaches to unravel the molecular complexity of proprotein-derived biomarkers and support their quantification: the examples of B-type natriuretic peptide and apelin peptides.
C. Mesmin (2012)
10.1146/ANNUREV.PHYSIOL.65.092101.142243
Cardiac hypertrophy: the good, the bad, and the ugly.
N. Frey (2003)
10.1152/AJPHEART.00238.2001
Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation.
Y. Liao (2002)
10.1016/j.jconrel.2012.04.009
Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery".
E. Mahon (2012)
10.1021/cr100440g
Protein-nanoparticle interactions: opportunities and challenges.
M. Mahmoudi (2011)
10.1016/j.peptides.2012.09.003
Cardiovascular effects of a PEGylated apelin
Z. Q. Jia (2012)
10.1161/01.CIR.0000120390.68287.BB
Hypertrophy of the heart: a new therapeutic target?
N. Frey (2004)
10.1073/PNAS.88.18.8277
Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy.
H. Rockman (1991)
10.1002/jps.23455
A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
A. Yuan (2013)
Acute stressinduced tissue injury in mice: differences between emotional and social stress. Cell Stress Chaperones 2002;7:36e46
O Sanchez (2002)
10.1016/0005-2736(93)90105-9
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.
G. Haran (1993)
10.1016/j.addr.2009.11.021
Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.
S. Gunaseelan (2010)
10.1007/s00395-007-0671-2
Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injury
J. C. Simpkin (2007)
10.1016/j.tips.2009.08.004
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
Y. Malam (2009)
10.1161/CIRCHEARTFAILURE.108.839761
Small animal models of heart failure: development of novel therapies, past and present.
R. Patten (2009)
Cardiac hypertrophy in hypertrophic cardiomyopathy and hypertension evaluated by echocardiography and body surface isopotential mapping.
H. Yoshida (1986)
10.1016/j.jconrel.2009.03.019
Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery.
S. Chono (2009)
Sustained release of growth factors.
S. Robinson (2002)
10.1016/j.jconrel.2008.05.009
Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives.
Huan Xu (2008)
10.1046/j.1471-4159.2000.0740034.x
Characterization of Apelin, the Ligand for the APJ Receptor
D. Lee (2000)
10.1016/j.jacc.2008.06.013
Vascular effects of apelin in vivo in man.
A. Japp (2008)
10.1021/nn202070n
Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
K. Choi (2011)
10.1615/CRITREVTHERDRUGCARRIERSYST.V29.I5.10
Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy.
P. Kumar (2012)



This paper is referenced by
10.2217/nnm.16.7
The potential for nanotechnology to improve delivery of therapy to the acute ischemic heart.
C. Evans (2016)
Effects of HOXB4 downstream targets on the haemopoietic differentiation of pluripotent stem cells
Maria Kydonaki (2016)
10.1089/dna.2016.3574
Caveolin-1-Autophagy Pathway Mediated Cardiomyocyte Hypertrophy Induced by Apelin-13.
D. Wu (2017)
10.1093/cvr/cvx061
ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage
T. Sato (2017)
10.18203/2319-2003.IJBCP20170322
Current evidence-based therapy does not restore plasma apelin level in phenotypically diverse chronic heart failure patients
Vinu Wilson (2017)
10.1152/ajpheart.00693.2017
Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.
Victoria N. Parikh (2018)
10.1007/978-3-030-20047-3_5
Nanobiomaterial Advances in Cardiovascular Tissue Engineering
M. J. Hill (2019)
10.1007/978-3-319-97852-9_18
Drug Encapsulation and Nanocarriers for Targeted Delivery in Animals
U. Jain (2019)
10.3389/fphar.2020.00256
Icariin Ameliorates Diabetic Cardiomyopathy Through Apelin/Sirt3 Signalling to Improve Mitochondrial Dysfunction
T. Ni (2020)
10.1016/j.freeradbiomed.2019.01.052
Ferritinophagy activation and sideroflexin1-dependent mitochondria iron overload is involved in apelin-13-induced cardiomyocytes hypertrophy.
Mingzhu Tang (2019)
10.1016/j.jconrel.2017.02.021
Revisiting structure‐property relationship of pH‐responsive polymers for drug delivery applications
Salime Bazban-Shotorbani (2017)
10.2147/IJN.S250872
Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases
Rajasekharreddy Pala (2020)
10.1161/HYPERTENSIONAHA.117.10156
Apelin Is a Negative Regulator of Angiotensin II–Mediated Adverse Myocardial Remodeling and Dysfunction
Zhen-Zhou Zhang (2017)
10.1097/MNH.0000000000000241
Apelin-13 in blood pressure regulation and cardiovascular disease
L. Yamaleyeva (2016)
10.1038/s41467-019-10591-5
Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure
Pablo Cordero (2019)
10.1038/srep19379
Combinatorial Treatment with Apelin-13 Enhances the Therapeutic Efficacy of a Preconditioned Cell-Based Therapy for Peripheral Ischemia
M. Samura (2016)
10.1080/14728222.2019.1561871
The apelin/APJ system as a therapeutic target in metabolic diseases
I. Castan-Laurell (2019)
10.17863/CAM.35320
The Identification and Pharmacological Characterisation of Novel Apelin Receptor Agonists In Vitro and In Vivo
Cai Read (2019)
10.1016/j.vph.2015.08.005
Apelinergic system in endothelial cells and its role in angiogenesis in myocardial ischemia.
Věra Nováková (2016)
10.1038/s41598-019-50980-w
Non-viral vector based gene transfection with human induced pluripotent stem cells derived cardiomyocytes
Shihua Tan (2019)
10.3109/02699052.2016.1140809
The effects of neuromuscular facilitation techniques on osteoporosis of hemiplegia limbs and serum leptin level in patients or rats with cerebral infarction
Zhihua Si (2016)
10.1016/j.jconrel.2020.11.002
Light-induced release of the cardioprotective peptide angiotensin-(1-9) from thermosensitive liposomes with gold nanoclusters.
J. Bejarano (2020)
10.1101/038174
A community overlap strategy reveals central genes and networks in heart failure
P. Cordero (2016)
10.1124/pr.119.017533
International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand
Cai Read (2019)
10.1111/nyas.14123
The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders
É. Marsault (2019)
10.1007/S11743-015-1757-8
Optimization of Phospholipid Nanoparticle Formulations Using Response Surface Methodology
Sumaira Naeem (2016)
10.1016/j.phrs.2020.105372
Peptidic vaccines: The new cure for heart diseases?
C. E. Guerrero-Beltrán (2020)
10.1097/CCM.0000000000002097
Apelin Compared With Dobutamine Exerts Cardioprotection and Extends Survival in a Rat Model of Endotoxin-Induced Myocardial Dysfunction*
F. Chagnon (2017)
10.1016/j.npep.2016.08.010
Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats
Z. Hajimashhadi (2017)
10.21276/ijlssr.2017.3.5.11
Biodegradable Nanoparticles for Delivering Drugs and Silencing Multiple Genes or Gene activation in Diabetic Nephropathy
Navneet Omprakash Soni (2017)
Nanodevices that acts as nanocarriers for controlled and directed drug delivery to select cells, organs or tissues in cardiovascular diseases.
Juan Manuel Vélez-Reséndiz (2017)
10.1101/038174
Pathologic gene network rewiring implicates PPP1R3A as a central cardioprotective factor in pressure overload heart failure
Pablo Cordero (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar